CA3050896C - Genetic factors associated with inhibitor development in hemophilia a - Google Patents

Genetic factors associated with inhibitor development in hemophilia a Download PDF

Info

Publication number
CA3050896C
CA3050896C CA3050896A CA3050896A CA3050896C CA 3050896 C CA3050896 C CA 3050896C CA 3050896 A CA3050896 A CA 3050896A CA 3050896 A CA3050896 A CA 3050896A CA 3050896 C CA3050896 C CA 3050896C
Authority
CA
Canada
Prior art keywords
individual
factor viii
fviii
snp
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3050896A
Other languages
English (en)
French (fr)
Other versions
CA3050896A1 (en
Inventor
Erik Berntorp
Jan Astermark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3050896A1 publication Critical patent/CA3050896A1/en
Application granted granted Critical
Publication of CA3050896C publication Critical patent/CA3050896C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3050896A 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a Active CA3050896C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32660210P 2010-04-21 2010-04-21
US61/326602 2010-04-21
CA2796561A CA2796561C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2796561A Division CA2796561C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Publications (2)

Publication Number Publication Date
CA3050896A1 CA3050896A1 (en) 2011-10-27
CA3050896C true CA3050896C (en) 2023-01-24

Family

ID=43983253

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3050896A Active CA3050896C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a
CA2796561A Active CA2796561C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2796561A Active CA2796561C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Country Status (7)

Country Link
US (3) US9637789B2 (https=)
EP (2) EP2730663B1 (https=)
JP (4) JP6058529B2 (https=)
AU (1) AU2011244228B2 (https=)
CA (2) CA3050896C (https=)
ES (1) ES2949953T3 (https=)
WO (1) WO2011131774A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
JP6058529B2 (ja) * 2010-04-21 2017-01-11 エリック ベルントルプ， 血友病ａにおけるインヒビターの発達と関連する遺伝因子
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
KR101774996B1 (ko) * 2016-06-23 2017-09-19 주식회사 녹십자지놈 혈우병 치료제의 효능 예측 마커 및 이의 용도
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DK1921169T3 (da) 1993-11-12 2012-06-04 Phri Properties Inc Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits
CA2240667A1 (en) 1995-12-18 1997-06-26 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
WO2008059009A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
JP6058529B2 (ja) * 2010-04-21 2017-01-11 エリック ベルントルプ， 血友病ａにおけるインヒビターの発達と関連する遺伝因子

Also Published As

Publication number Publication date
EP2730663B1 (en) 2023-03-22
CA3050896A1 (en) 2011-10-27
US20120065077A1 (en) 2012-03-15
AU2011244228B2 (en) 2015-07-30
US9637789B2 (en) 2017-05-02
JP6189904B2 (ja) 2017-08-30
US9644239B2 (en) 2017-05-09
ES2949953T3 (es) 2023-10-04
WO2011131774A1 (en) 2011-10-27
EP2730663A2 (en) 2014-05-14
CA2796561C (en) 2019-09-17
JP2017200491A (ja) 2017-11-09
US20110312519A1 (en) 2011-12-22
US20180016635A1 (en) 2018-01-18
AU2011244228A1 (en) 2012-11-08
EP2561090A1 (en) 2013-02-27
JP2013529071A (ja) 2013-07-18
JP6058529B2 (ja) 2017-01-11
JP2015226551A (ja) 2015-12-17
JP2019180421A (ja) 2019-10-24
CA2796561A1 (en) 2011-10-27
EP2730663A3 (en) 2014-09-10
JP6568162B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
CA3050896C (en) Genetic factors associated with inhibitor development in hemophilia a
Eikenboom et al. Recessive inheritance of von Willebrand's disease type I
Kallaur et al. Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis
Thibault Flesher et al. Recent advances in the genetics of systemic lupus erythematosus
Dickinson et al. Polymorphisms of cytokine and innate immunity genes and GVHD
Nicol et al. The autoimmune concept of multiple sclerosis
Zhang et al. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease
Lough et al. Abnormal CX3CR1+ lamina propria myeloid cells from intestinal transplant recipients with NOD2 mutations
Pellenz et al. The rs2304256 polymorphism in TYK2 gene is associated with protection for type 1 diabetes mellitus
Stridh et al. Parent-of-origin effects implicate epigenetic regulation of experimental autoimmune encephalomyelitis and identify imprinted Dlk1 as a novel risk gene
EP3510410A1 (en) Use of recombinant lymphocyte activation gene-3
Gu et al. Polymorphism of stromal cell-derived factor-1 selectively upregulates gene expression and is associated with increased susceptibility to coronary artery disease
JP2008524999A (ja) 精神障害を治療するための組成物及び方法
Wang et al. Interleukin-6 receptor gene polymorphisms were associated with sporadic Alzheimer's disease in Chinese Han
AU2017239514B2 (en) Genetic factors associated with inhibitor development in hemophilia a
JP2008525000A (ja) 統合失調症及び関連障害を治療するための組成物及び方法
Mescheriakova et al. Genetics of multiple sclerosis
El-Akawi et al. The role of cytotoxic T-lymphocyte associated antigen 4 (CTLA4)+ 49A/G and tumor necrosis factor alpha (TNF-α)-308G/A polymorphism in the development of celiac disease in Jordanian patients
Sadeghi The contribution of interleukin-1 and retinoid acid receptor-related orphan receptor alpha to the pathogenesis of epidermolysis bullosa acquisita
HK1197923A (en) Genetic factors associated with inhibitor development in hemophilia a
HK1197923B (en) Genetic factors associated with inhibitor development in hemophilia a
Binding Polymorphism in the Innate Immune
Bykanova et al. [PP. 07.13] THE C3435T POLYMORPHISM OF THE ABCB1 GENE INCREASES THE RISK OF ESSENTIAL HYPERTENSION IN CIGARETTE SMOKERS
Veropalumbo Analysis of the co-inheritance between FV Leiden and/or FVHis1299Arg and/or other mutations as a possible individual risk factor of thromboembolic venous disease (CHAMPION study).
Uruski et al. [PP. 07.14] DISCOVERY OF JAK/STAT SIGNALLING PATHWAY SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATING WITH PRIMARY ARTERIAL HYPERTENSION

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190731

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829